Genmab Announces Financial Results for the First Half of 2023
August 03, 2023 11:01 ET
|
Genmab A/S
August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights EPKINLY™ (epcoritamab-bysp) was approved by the U.S. Food and Drug Administration (U.S....
Genmab Updates 2023 Financial Guidance
July 27, 2023 18:01 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; July 28, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its preliminary first half 2023 financial results and its updated 2023 financial guidance. ...
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
July 21, 2023 04:30 ET
|
Genmab A/S
Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary efficacy and safety of epcoritamab in patients with...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
July 20, 2023 06:22 ET
|
Genmab A/S
Company Announcement Net sales of DARZALEX® in the second quarter of 2023 totaled USD 2,431 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
June 27, 2023 18:49 ET
|
Genmab A/S
Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage with global regulatory authorities to discuss next stepsData from the clinical...
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
June 22, 2023 07:00 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; June 22, 2023 – Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody, has been added to the National Comprehensive Cancer...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
June 20, 2023 14:45 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 20, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 19,395 shares as a consequence of the exercise of employee warrants. The...
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
June 09, 2023 03:01 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; June 9, 2023, at 9:00am CEST Results from phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in combination with rituximab-lenalidomide (R2) showed a 98...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
June 08, 2023 17:22 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 8, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the...
Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023 02:00 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Goldman Sachs 44th...